From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
DDR1-IN-5 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 7.36 nM. DDR1-IN-5 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 4.1 nM. DDR1-IN-5 has anti-cancer activity . DDR1-IN-5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
DDR1-IN-6 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 9.72 nM. DDR1-IN-6 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 9.7 nM. DDR1-IN-6 has anti-cancer activity . DDR1-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
DDR1/2 inhibitor-2 (Example 31) is a DDR1/DDR2 inhibitor, with IC50 values less than 100 nM. DDR1/2 inhibitor-2 can be used for research of cancer and fibrotic diseases .
DDR1-IN-4 (Compound 2.45) is a selective and potent Discoidin Domain Receptor 1 (DDR1) autophosphorylation inhibitor, with IC50 values of 29 nM and 1.9 μM for DDR1 and DDR2, respectively .
5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone (DDR) is an anticancer agent that can be extracted from Indigofera ovata. 5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone can inhibit the PI3K/AKT and NF-кB pathways, inhibit the invasion and migration of cancer cells, and has anticancer activity .
DDR1 Human Pre-designed siRNA Set A contains three designed siRNAs for DDR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
DDR1-IN-8 (compound 7s) is a potent inhibitor of DDR1/2, with the IC50 values of 0.045 μM and 0.126 μM, respectively. DDR1-IN-8 has anti-tumor activity .
DDR1-IN-10 (compound 7q) is a DDR1 inhibitor. DDR1-IN-10 can be used in the study of pancreatic cancer, non-small cell lung cancer, and gastric carcinoma .
DDR1-IN-1 dihydrochloride is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC50 of 105 nM; 4-fold less potent for DDR2 (IC50 = 413 nM) .
DDR1-IN-9 is a selective inhibitor of DDR1 with significant kinase activity suppression, exhibiting a Kd value of 4.7 nM and an IC50 value of 9.4 nM. DDR1-IN-9 demonstrates reduced potency against a diverse panel of 400 nonmutated kinases, indicating its specificity. Additionally, DDR1-IN-9 shows favorable pharmacokinetic properties and potential therapeutic effects in a model of pulmonary fibrosis.
DDR1/2 inhibitor-3 (5n) is a DDR1/2 inhibitor, with IC50 valuesof 9.4 and 20.4 nM, respectively. DDR1/2 inhibitor-3 can be used in anti-inflammatory research .
DDR1-IN-11 (Compound 4) is an inhibitor of Discoidin domain receptor 1 (DDR1) with an IC50 of 46.16 nM. DDR1-IN-11 can achieve an inhibition rate of 99.86% against Z-138 cells at a concentration of 10 μM, and it can be used in the research of acute myeloid leukemia (AML) .
DDR Inhibitor 2 (compound 5a) is a discoidin domain receptor (DDR) inhibitor with an IC50 of 0.125 μM. DDR Inhibitor 2 can be used for study of fibrotic diseases .
DDR1 ligand 1 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). DDR1 ligand 1 can be used for the synthesis of PROTAC DDR1 degrader-1 (HY-176184) .
7rh (DDR1-IN-2) is a potent inhibitor of discoidin domain receptor 1(DDR1), with an IC50 of 13.1 nM, and also less potently inhibits DDR2, with an IC50 of 203 nM. 7rh is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Ddr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ddr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ddr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ddr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ddr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ddr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ddr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ddr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
DDR2 Human Pre-designed siRNA Set A contains three designed siRNAs for DDR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Anti-DDR1/CD167a Antibody is a CHO-expressed human antibody that targets DDR1/CD167a. The Anti-DDR1/CD167a Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DDR1/CD167a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM and 3.2 nM, respectively. Antitumor activity .
BTX161, a thalidomide analog, is an effective CKIα degrader. BTX161 mediates human AML cell CKIα degradation more effectively than lenalidomide and activates the DNA damage response (DDR) and p53, while stabilizing p53 antagonist MDM2.
UNC-2170 maleate is the maleate salt form of UNC-2170 (HY-115531). UNC-2170 maleate is a selective inhibitor for the methyl-lysine binding protein 53BP1, with IC50 of 29 µM and Kd of 22 µM. UNC-2170 maleate shows at least 17-fold selectivity for 53BP1 as compared to nine other methyl-lysine (Kme) reader proteins. 53BP1 is a Kme binding protein that plays a central role in DNA Damage Repair (DDR) pathways and is recruited to sites of double-strand breaks (DSB) .
VU6015929 is a potent, selective and orally active dual discoidin domain receptor 1/2 (DDR1/2) inhibitor with IC50s of 4.67 nM and 7.39 nM, respectively. VU6015929 potently blocks collagen-induced DDR1 activation and collagen-IV production .
SR-302 is a potent and selectivity DDR/p38 inhibitor, with IC50 values of 0.125, 0.023 and 0.018 μM for p38α, DDR1 and DDR2, respectively. SR-302 can be used for the research of fibrotic disorders, such as renal and pulmonary fibrosis, atherosclerosis, and various forms of cancer .
LLC355 is a discoidin domain receptor 1 (DDR1) ATTEC degrader. LLC355 efficiently degrades DDR1 protein with a DC50 value of 150.8 nM in non-small cell lung cancer NCI-H23 cells. LLC355 induces DDR1 degradation via lysosome-mediated autophagy. LLC355 potently inhibits cancer cell tumorigenicity, migration, and invasion .
Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib (LY2801653) also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM) .
Selenocystine is a broad-spectrum anti-cancer agent. Selenocystine induces DNA damage in HepG2 cells, particularly in the form of DNA double strand breaks (DSBs). Selenocystine exhibits great promise as a therapeutic or adjuvant agent targeting DNA repair for cancer treatment .
Nimustine is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity .
EPIC-0628 is an inhibitor of the HOTAIR-EZH2 interaction and promotes ATF3 expression. The long noncoding RNA HOTAIR has been found to regulate glioblastoma (GBM) progression and mediate DNA damage repair (DDR) by interacting with the catalytic subunit EZH2 of PRC2. EPIC-0628 also inhibits the ATF3-p38-E2F1 DDR pathway to inhibit the HR pathway and upregulates CDKN1A (p21) expression, causing cell cycle arrest. EPIC-0628 also synergizes with Temozolomide (TMZ) (HY-17364) to enhance its in vivo potency .
ATR-IN-23 (Compound 34) is a potent and selective ATR inhibitor with an IC50 of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers .
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis .
Recombinant Humanized Type III Collagen 10.4kDa is a novel biomaterial that have anticancer effects. Recombinant Humanized Type III Collagen 10.4kDa activates discoidin domain receptor 1 (DDR1), and thus inhibits autophagy, proliferation, and migration of cancer cells, and induces apoptosis .
Lenalidomide-5-Br-amide-C2-Br is an E3 ligase ligand-linker conjugate. Lenalidomide-5-Br-amide-C2-Br can be used to synthesize PROTAC DDR1 degrader-1 (HY-176184) .
JNK3 inhibitor-2 is a potent and selective JNK3 inhibitor with IC50 values of >100, >100, 0.25 µM for JNK1, JNK2, JNK3, respectively. JNK3 inhibitor-2 shows DDR1 and EGFR (T790M, L858R) inhibition .
Nimustine hydrochloride (ACNU) is the hydrochloride salt form of Nimustine (HY-13703). Nimustine hydrochloride is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine hydrochloride activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity .
ATM Inhibitor-3 (compound 34) is a potent and selective ATM inhibitor, with an IC50 of 0.71 nM. ATM Inhibitor-3 shows inhibition of PI3K kinases family. ATM Inhibitor-3 exhibits favorable metabolic stability .
ATM Inhibitor-4 (compound 39) is a potent and selective ATM inhibitor, with an IC50 of 0.32 nM. ATM Inhibitor-4 shows stronger inhibition of PI3K kinases family. ATM Inhibitor-4 shows a full inhibition of mTOR at 1 μM. ATM Inhibitor-4 exhibits favorable metabolic stability .
GW694590A (UNC10112731) is a MYC protein stabilizer that increases endogenous MYC protein levels. GW694590A also targets receptor tyrosine kinases, inhibiting DDR2, KIT and PDGFRα by 81% at 1 μM. , 68% and 67%. GW694590A is a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential effects on the Fluc reporter gene .
WRG-28-d5 is the deuterium labeled WRG-28(HY-114169).WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor, with an IC50 of 230 nM. WRG-28 inhibits tumor invasion, migration and tumor-supporting effects of cancer-associated fibroblasts (CAFs). WRG-28 inhibits metastatic
WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor, with an IC50 of 230 nM. WRG-28 inhibits tumor invasion, migration and tumor-supporting effects of cancer-associated fibroblasts (CAFs). WRG-28 inhibits metastatic breast tumor cell colonization in the lungs. WRG-28 also shows good activity of relieving rheumatoid arthritis in CAIA model of mice .
ATR-IN-11 (Compound Hit01) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. ATR kinase is a key regulating protein within the DNA damage response (DDR), responsible for sensing replication stress (RS). ATR-IN-11 is a promising lead compound for subsequent agent discovery targeting ATR kinase. ATR-IN-11 has the potential for the research of cancer disease .
BSJ-4-116 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC) with an IC50 of 6 nM. BSJ-4-116 downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation). BSJ-4-116 exhibits potent antiproliferative effects, alone and in combination with the poly(ADP-ribose) polymerase inhibitor Olaparib (HY-10162) .
ML786 dihydrochloride is a potent and orally bioavailable Raf inhibitor, with IC50s of 2.1, 4.2, and 2.5 nM for V600EΔB-Raf, wt B-Raf, and C-Raf, respectively. ML786 dihydrochloride also inhibits Abl-1, DDR2, EPHA2, KDR, and RET (IC50=<0.5, 7.0, 11, 6.2, 0.8 nM). ML786 dihydrochloride can be used for the research of cancers .
CIDD-8633 is a potent DDR2 inhibitor with an IC50 of 6.105 μM. CIDD-8633 significantly reduces the proliferation of MIA-PaCa-2 cells and AsPC-1 with IC25s of 4.0 and 5.5 μM, respectively. CIDD-8633 inhibits cell migration and halts the cell cycle and induces apoptosis, significantly suppressing pancreatic ductal adenocarcinoma (PDAC) tumor growth. CIDD-8633 can be used for the study of pancreatic cancer such as PDAC .
ML786 is a potent and orally bioavailable Raf inhibitor, with IC50s of 2.1, 4.2, and 2.5 nM for V600EΔB-Raf, wt B-Raf, and C-Raf, respectively. ML786 also inhibits Abl-1, DDR2, EPHA2, KDR, and RET (IC50=<0.5, 7.0, 11, 6.2, 0.8 nM). ML786 can be used for the research of cancers .
UNC-2170 is a functionally active, fragment-like ligand for 53BP1 (IC50=29 µM; Kd=22 µM). UNC-2170 shows at least 17-fold selectivity for 53BP1 as compared to nine other methyl-lysine (Kme) reader proteins. 53BP1 is a Kme binding protein that plays a central role in DNA Damage Repair (DDR) pathways and is recruited to sites of double-strand breaks (DSB) .
CDK12/13-IN-3 (Compound 12b) is the orally active inhibitor for CDK that inhibits CDK12 and CDK13 with IC50 of 107.4 nM and 79.4 nM. CDK12/13-IN-3 inhibits the phosphorylation of Ser2 on the CTD of RNA polymerase II, induces DNA damage, and downregulates the gene expression of DNA damage response (DDR). CDK12/13-IN-3 exhibits antiproliferative activity against multiple cancer cells with IC50 of nanomolar levels. CDK12/13-IN-3 exhibits antitumor effect in mouse models, exhibits good pharmacokinetic properties with an oral bioavailability of 53.6% .
USP1-IN-11 (compound 38-P2) is a selective, reversible, and noncompetitive USP1 (Ubiquitin-specific protease 1) inhibitor. USP1-IN-11 activates the DDR (DNA damage repair) pathway, induces cell cycle arrest and cell Apoptosis, and inhibits cell survival. USP1-IN-11 enhances the sensitivity of Olaparib (HY-10162)-resistant cells to Olaparib (HY-10162) and shows a synergetic effect with Andrographolide (HY-N0191) in BRCA-proficient cancer cells. USP1-IN-11 displays significant, dose-dependent antitumor efficacy in the MDA-MB-436 xenograft model .
SJ11646 is a Dasatinib (HY-10181)-based LCKPROTAC degrader with a DC50 of 0.00838 pM. SJ11646 has potent cytotoxicity against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples with drastically prolonged suppression of LCK signaling, and induces T-ALL apoptosis. SJ11646 binds to 51 human kinases with a high affinity (particularly ABL1, KIT, and DDR1). SJ11646 has superior antileukemic efficacy in T-ALL mice model. . Pink: LCK ligand (HY-107447); Blue: CRBN ligase ligand (HY-163169); Black: linker (HY-76667)
Recombinant Humanized Type III Collagen 10.4kDa is a novel biomaterial that have anticancer effects. Recombinant Humanized Type III Collagen 10.4kDa activates discoidin domain receptor 1 (DDR1), and thus inhibits autophagy, proliferation, and migration of cancer cells, and induces apoptosis .
Selenocystine is a broad-spectrum anti-cancer agent. Selenocystine induces DNA damage in HepG2 cells, particularly in the form of DNA double strand breaks (DSBs). Selenocystine exhibits great promise as a therapeutic or adjuvant agent targeting DNA repair for cancer treatment .
Anti-DDR1/CD167a Antibody is a CHO-expressed human antibody that targets DDR1/CD167a. The Anti-DDR1/CD167a Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DDR1/CD167a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Selenocystine is a broad-spectrum anti-cancer agent. Selenocystine induces DNA damage in HepG2 cells, particularly in the form of DNA double strand breaks (DSBs). Selenocystine exhibits great promise as a therapeutic or adjuvant agent targeting DNA repair for cancer treatment .
5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone (DDR) is an anticancer agent that can be extracted from Indigofera ovata. 5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone can inhibit the PI3K/AKT and NF-кB pathways, inhibit the invasion and migration of cancer cells, and has anticancer activity .
The DDR1 protein is a fibrillar collagen receptor that coordinates key cellular processes including matrix remodeling, migration, differentiation, survival, and proliferation.Upon collagen binding, DDR1 activates signaling cascades involving SRC and MAP kinases, promoting matrix remodeling through MMP upregulation, promoting cell migration, wound healing, and tumor invasion.DDR1 Protein, Rat (HEK293, His) is the recombinant rat-derived DDR1 protein, expressed by HEK293 , with C-His labeled tag.
The DDR1 protein is a tyrosine kinase and cell surface receptor for fibrillar collagen that tightly regulates cell attachment and affects extracellular matrix processes. Upon collagen binding, DDR1 initiates a signaling cascade involving SRC, activating MAP kinase. DDR1 Protein, Human (HEK293, His) is the recombinant human-derived DDR1 protein, expressed by HEK293 , with C-His labeled tag.
The DDR1 protein is a fibrillar collagen receptor that coordinates key cellular processes including matrix remodeling, migration, differentiation, survival, and proliferation. Upon collagen binding, DDR1 activates signaling cascades involving SRC and MAP kinases, promoting matrix remodeling through MMP upregulation, promoting cell migration, wound healing, and tumor invasion. DDR1 Protein, Mouse (HEK293, His, solution) is the recombinant mouse-derived DDR1 protein, expressed by HEK293 , with C-His labeled tag.
The DDR2 protein is a tyrosine kinase and cell surface receptor for fibrillar collagen that critically regulates cell differentiation, extracellular matrix remodeling, migration, and proliferation.DDR2 is crucial for bone development.It affects osteoblast differentiation and chondrocyte maturation through the MAP kinase signaling pathway and activates the transcription factor RUNX2.DDR2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived DDR2 protein, expressed by HEK293 , with C-6*His labeled tag.
The DDR2 protein is a tyrosine kinase critical in tissue remodeling, acting as a cell surface receptor for fibrillar collagen and affecting cell differentiation, extracellular matrix remodeling, migration, and proliferation. DDR2 is critical for bone development and centrally regulates osteoblast differentiation and chondrocyte maturation through MAP kinase signaling and activation of RUNX2. DDR2 Protein, Rat (HEK293, His) is the recombinant rat-derived DDR2 protein, expressed by HEK293 , with C-His labeled tag.
The DDR1 protein is a fibrillar collagen receptor that coordinates key cellular processes including matrix remodeling, migration, differentiation, survival, and proliferation.Upon collagen binding, DDR1 activates signaling cascades involving SRC and MAP kinases, promoting matrix remodeling through MMP upregulation, promoting cell migration, wound healing, and tumor invasion.DDR1 Protein, Rat (HEK293, hFc) is the recombinant rat-derived DDR1 protein, expressed by HEK293 , with C-hFc labeled tag.
The DDR1 protein is a fibrillar collagen receptor that coordinates key cellular processes including matrix remodeling, migration, differentiation, survival, and proliferation. Upon collagen binding, DDR1 activates signaling cascades involving SRC and MAP kinases, promoting matrix remodeling through MMP upregulation, promoting cell migration, wound healing, and tumor invasion. DDR1 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived DDR1 protein, expressed by HEK293 , with C-hFc labeled tag.
The DDR1 protein is a fibrillar collagen receptor that coordinates key cellular processes including matrix remodeling, migration, differentiation, survival, and proliferation. Upon collagen binding, DDR1 activates signaling cascades involving SRC and MAP kinases, promoting matrix remodeling through MMP upregulation, promoting cell migration, wound healing, and tumor invasion. DDR1 Protein, Mouse (sf9, His-GST) is the recombinant mouse-derived DDR1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.
The DDR1 protein is a tyrosine kinase and cell surface receptor for fibrillar collagen that tightly regulates cell attachment and affects extracellular matrix processes. Upon collagen binding, DDR1 initiates a signaling cascade involving SRC, activating MAP kinase. DDR1 Protein, Human (sf9, His-GST) is the recombinant human-derived DDR1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.
The DDR2 protein is a tyrosine kinase critical in tissue remodeling, acting as a cell surface receptor for fibrillar collagen and affecting cell differentiation, extracellular matrix remodeling, migration, and proliferation. DDR2 is critical for bone development and centrally regulates osteoblast differentiation and chondrocyte maturation through MAP kinase signaling and activation of RUNX2. DDR2 Protein, Rat (HEK293, hFc) is the recombinant rat-derived DDR2 protein, expressed by HEK293 , with C-hFc labeled tag.
The DDR2 protein is a tyrosine kinase critical in tissue remodeling, acting as a cell surface receptor for fibrillar collagen and affecting cell differentiation, extracellular matrix remodeling, migration, and proliferation. DDR2 is critical for bone development and centrally regulates osteoblast differentiation and chondrocyte maturation through MAP kinase signaling and activation of RUNX2. DDR2 Protein, Human (HEK293, Fc) is the recombinant human-derived DDR2 protein, expressed by HEK293 , with C-hFc labeled tag.
The DDR2 protein is a tyrosine kinase critical in tissue remodeling, acting as a cell surface receptor for fibrillar collagen and affecting cell differentiation, extracellular matrix remodeling, migration, and proliferation. DDR2 is critical for bone development and centrally regulates osteoblast differentiation and chondrocyte maturation through MAP kinase signaling and activation of RUNX2. DDR2 Protein, Human (HEK293, His) is the recombinant human-derived DDR2 protein, expressed by HEK293 , with C-His labeled tag.
The DDR2 protein is a tyrosine kinase critical in tissue remodeling, acting as a cell surface receptor for fibrillar collagen and affecting cell differentiation, extracellular matrix remodeling, migration, and proliferation. DDR2 is critical for bone development and centrally regulates osteoblast differentiation and chondrocyte maturation through MAP kinase signaling and activation of RUNX2. DDR2 Protein, Human (sf9, GST) is the recombinant human-derived DDR2, expressed by Sf9 insect cells , with GST labeled tag.
The DDR2 protein is a tyrosine kinase critical in tissue remodeling, acting as a cell surface receptor for fibrillar collagen and affecting cell differentiation, extracellular matrix remodeling, migration, and proliferation. DDR2 is critical for bone development and centrally regulates osteoblast differentiation and chondrocyte maturation through MAP kinase signaling and activation of RUNX2. DDR2 Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived DDR2 protein, expressed by HEK293 , with C-hFc labeled tag.
The DDR2 protein is a tyrosine kinase critical in tissue remodeling, acting as a cell surface receptor for fibrillar collagen and affecting cell differentiation, extracellular matrix remodeling, migration, and proliferation. DDR2 is critical for bone development and centrally regulates osteoblast differentiation and chondrocyte maturation through MAP kinase signaling and activation of RUNX2. DDR2 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived DDR2 protein, expressed by HEK293 , with C-His labeled tag.
The DDR2 protein is a tyrosine kinase critical in tissue remodeling, acting as a cell surface receptor for fibrillar collagen and affecting cell differentiation, extracellular matrix remodeling, migration, and proliferation. DDR2 is critical for bone development and centrally regulates osteoblast differentiation and chondrocyte maturation through MAP kinase signaling and activation of RUNX2. DDR2 Protein, Human (sf9, His-GST) is the recombinant human-derived DDR2 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.
The DDR1 protein is a fibrillar collagen receptor that coordinates key cellular processes including matrix remodeling, migration, differentiation, survival, and proliferation. Upon collagen binding, DDR1 activates signaling cascades involving SRC and MAP kinases, promoting matrix remodeling through MMP upregulation, promoting cell migration, wound healing, and tumor invasion. DDR1 Protein, Mouse (HEK293, C-His) is the recombinant mouse-derived DDR1, expressed by HEK293, with C-6*His labeled tag. The total length of DDR1 Protein, Mouse (HEK293, C-His) is 395 a.a..
The DDR1 protein is a tyrosine kinase and cell surface receptor for fibrillar collagen that tightly regulates cell attachment and affects extracellular matrix processes. Upon collagen binding, DDR1 initiates a signaling cascade involving SRC, activating MAP kinase. DDR1 Protein, Human (HEK293, Fc) is the recombinant human-derived DDR1 protein, expressed by HEK293, with C-hFc labeled tag.
DR3/TNFRSF25 Protein displays a deficiency in conserved residue(s) crucial for feature annotation propagation. DR3/TNFRSF25 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived DR3/TNFRSF25 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of DR3/TNFRSF25 Protein, Cynomolgus (HEK293, Fc) is 184 a.a., with molecular weight of 50-60 kDa.
The DR3/TNFRSF25 protein displays defects in conserved residues critical for propagation feature annotation. This defect in DR3/TNFRSF25 prevents the propagation of specific functional features associated with this protein. DR3/TNFRSF25 Protein, Mouse (HEK293, His) is the recombinant mouse-derived DR3/TNFRSF25 protein, expressed by HEK293 , with C-His labeled tag.
WRG-28-d5 is the deuterium labeled WRG-28(HY-114169).WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor, with an IC50 of 230 nM. WRG-28 inhibits tumor invasion, migration and tumor-supporting effects of cancer-associated fibroblasts (CAFs). WRG-28 inhibits metastatic
DDR2 Antibody (YA4319) is a mouse-derived and non-conjugated IgG2a antibody, targeting to DDR2. It can be applicated for IHC-P, ICC/IF, FC, ELISA assays, in the background of human, mouse, rat, rabbit.
DDR2; NTRKR3; TKT; TYRO10; Discoidin domain-containing receptor 2; Discoidin domain receptor 2; CD167 antigen-like family member B; Discoidin domain-containing receptor tyrosine kinase 2; Neurotrophic tyrosine kinase; receptor-related 3; Re
WB
Human, Mouse, Rat
DDR2 Antibody (YA3367) is a non-conjugated IgG antibody, targeting DDR2, with a predicted molecular weight of 97 kDa (observed band size: 97 kDa). DDR2 Antibody (YA3367) can be used for WB experiment in human, mouse, rat background.
DDR1 Antibody (YA4811) is a mouse-derived and non-conjugated monoclonal antibody, targeting to DDR1. It can be applicated for WB, ELISA assays, in the background of human.
DDR2; NTRKR3; TKT; TYRO10; Discoidin domain-containing receptor 2; Discoidin domain receptor 2; CD167 antigen-like family member B; Discoidin domain-containing receptor tyrosine kinase 2; Neurotrophic tyrosine kinase; receptor-related 3; Re
WB, IHC-P, ICC/IF, ELISA
Human
DDR2 Antibody (YA4812) is a mouse-derived and non-conjugated monoclonal antibody, targeting to DDR2. It can be applicated for WB, IHC-P, ICC/IF, ELISA assays, in the background of human.
TNFRSF25 Antibody (YA4413) is a mouse-derived and non-conjugated IgG1 antibody, targeting to TNFRSF25. It can be applicated for IHC-P, FC, ELISA assays, in the background of human.
DDR1 Human Pre-designed siRNA Set A contains three designed siRNAs for DDR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ddr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ddr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ddr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ddr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ddr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ddr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ddr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ddr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
DDR2 Human Pre-designed siRNA Set A contains three designed siRNAs for DDR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
